Universal Ibogaine Inc
- LAST PRICE0.0150
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0100/ 675
- Ask / Lots0.0150/ 2
- Open / Previous Close0.0150 / 0.0150
- Day Range
- 52 Week Range
- Volume5,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBO |
|---|
Apr 29, 2024
Universal Ibogaine provides update on planned Clinical Trial Application process, from 6:00AM ET on Monday Apr 29, 2024 by Dow Jones
6:00AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 22, 2024
Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders, from 9:00AM ET on Monday Apr 22, 2024 by Dow Jones
9:00AM ET on Monday Apr 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Universal Ibogaine Inc | 4.4M | -2.4x | --- |
Sproutly Canada Inc | 5.4M | -0.5x | --- |
Revitalist Lifestyle and Wellness Ltd | 2.8M | -0.1x | --- |
Element Lifestyle Retirement Inc | 1.1M | -1.9x | --- |
Braxia Scientific Corp | 842.9K | -0.1x | --- |
Moss Genomics Inc | 894.5K | -1.6x | --- |
Company Information
Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is focused on developing a network of addiction treatment clinics and undertake a planned clinical trial for research into the use of ibogaine for addiction treatment. Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. Ibogaine is a neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state. Ibogaine has demonstrated effectiveness in treating opioid use disorder and it appears to eliminate the painful symptoms of opioid withdrawal and provides a several month window free of drug cravings. Ibogaine targets multiple receptor sites in the brain when it manages dopamine and serotonin circuits and stimulates new brain cell growth.
Contact Information
- Headquarters
- (c/o Suite 600 - 815 8th Avenue SWCALGARY, AB, Canada T2P 3P2
- Phone
- 403-870-1841
- Fax
- 403-870-1841
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 291.1M |
Universal Ibogaine Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.01 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
